Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.
Staying in a hotel or private accommodation has been associated with carrying ESBL-producing bacteria in travelers to low- and middle-income countries, according to research presented at ECCMID.
New research presented at ECCMID has identified a novel association between antimicrobial resistance and climatic factors in Europe.
Economist, Lord Jim O’Neill, has suggested that nationalized or state-run drug companies could be the answer to the lack of investment in antibiotic development.
An international study has compared the number of antibiotic resistance genes in water treatment plants across European countries, discovering that this correlates with the number of resistant bacteria in patient samples and antibiotic consumption across the region.
New research from the Stevens Institute of Technology has developed a microgel coating for implanted medical devices that can release micro-doses of antibiotics on bacterial contact, potentially combatting infection.
Could the development of products that produce a constant level of exogenous Reactive Oxygen® be beneficial in preventing and treating polymicrobial wound infections? Discover the potential of this avenue for multi-drug resistant organisms and more in our latest opinion piece.
The World Health Organization has released a new Technical Note updating countries worldwide on optimal methods and diagnostic techniques to improve antimicrobial resistance surveillance.
Researchers from Newcastle University have reported the presence of antibiotic-resistant genes in one of the most remote, ‘unspoiled’ regions on Earth.
The UK government has published a 20-year vision and a 5-year national action plan for how the UK will contribute to controlling and containing antimicrobial resistance by 2040.
